Treatment of metastatic prostate cancer. Lessons from the androgen receptor (Q40938127)

25 September 2017

1 reference

title

Treatment of metastatic prostate cancer. Lessons from the androgen receptor (English)

1 reference

25 September 2017

Bubley GJ

1 reference

25 September 2017

Balk SP

series ordinal

1 reference

25 September 2017

language of work or name

1 reference

1 June 1996

1 reference

Hematology / Oncology Clinics of North America

25 September 2017

published in

1 reference

25 September 2017

1 reference

25 September 2017

1 reference

25 September 2017

page(s)

713-725

1 reference

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Gene regulation by steroid hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Casodex--mechanisms of action and opportunities for usage

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Management of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

A transcriptional co-repressor that interacts with nuclear hormone receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Effects of high-dose ketoconazole treatment on adrenal mineralocorticoid biosynthesis in dogs and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Basis for hormonal management of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Suramin and prostate cancer: The role of hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Domains of the Human Androgen Receptor Involved in Steroid Binding, Transcriptional Activation, and Subcellular Localization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Ketoconazole and liarozole in the treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

1 reference

7 January 2021

Androgen receptor gene mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Androgen receptor expression in human tissues: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Androgen receptor gene mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Tamoxifen in advanced prostatic carcinoma. A dose escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970363-4

7 January 2021

10.1016/S0889-8588(05)70363-4

Identifiers

DOI

1 reference

25 September 2017

1 reference